OncoLink Cancer Treatment and Resources

Should We Treat the Regional Nodes in Patients with Skin Cancer of the Head and Neck with Perineural Invasion



Reviewer: William Levin, MD
OncoLink
Last Modified: October 7, 2002

Presenter: A. Garcia-Serra
Presenter's Affiliation: Department of Radiation Oncology, University of Florida, Gainesville, FL, USA
Type of Session: Scientific

Background

  • Once the decision to treat a patient with radiation therapy has been made, the next most important isuue is to dermine what area to treat.
  • While increasing the size of the radiation field allows for better coverage of subclinical disease this practice also increases exposure of normal tissue and the potential for side-effects.
  • In the current study, investigators try to determine the optimal treatment fields for skin cancer of the head and neck.
  • They have focused the study on patients who have microscopic or clinical perineural invasion (PNI), potentially representing high-risk disease.

Materials and Methods

  • This is a retrospective analysis of 135 patients.
  • All patients had non-melanomatous skin cancer and either microscopic or clinical PNI.
  • Clinical PNI was defined as cranial nerve involvement either by physical exam or by radiographic study.
  • Median radiation dose to the primary site was 65 Gy.
  • In 60% of patients with only microscopic PNI, elective neck lymph node irradiation was not performed.
  • Minimum follow-up was 2 years.

Results

  • The 5 year local control rates without salvage therapy were 87% for microscopic PNI-only, and 55% for patients with clinical PNI.
  • Overall, 88% of the local failures were associated with positive surgical margins.
  • Almost half of the recurrences in patients with microscopic PNI were limited to the first-echelon lymph nodes (usually the parotid region).
  • In the patients with clinical PNI, 90% of recurrences took place at the primary site.
  • Cranial nerve deficits rarely improved after treatment.
  • In patients with clinically progressive disease, radiographic abnormalities remained stable 30% of the time.

Author's Conclusions

  • First-echelon lymph nodes should be treated in all patients who have microscopic or clinical evidence of PNI.
  • Local control rates are poor for patients with clinical evidence of PNI.

Clinical/Scientific Implications

  • This study confirms the belief that PNI (either clinical or microscopic) represents high risk disease and requires elective neck node irradiation.
  • Clincal PNI represents especially bad disease and is not well controlled with radiation therapy alone at current radiation doses.

Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.

OncoLink I wish u knew...

Dr. Rustgi discusses genomics and cancer and translating laboratory research into clinical practice. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS